Innovation

Intelligent Antibacterial Therapeutic

Schepens Eye Research Institute
posted on 02/04/2010

Age-related macular degeneration (AMD) is caused by the deterioration of the central portion of the retina, the inside back layer of the eye. The diagnosis of AMD depends on dilated eye examination by an ophthalmologist: typically, the early visible signs of AMD include presence of yellow subretinal deposits called drusen, pigment migration of the retinal pigment epithelium and small areas of retinal atrophy. Unfortunately, it takes years for these clinical signs to develop, when the disease is well into its course.In an effort to develop an early diagnosis of AMD, Dr. Lashkari has studied the role of cytokines in the pathogenesis of age-related macular degeneration and found that serum concentrations of IP-10 and Eotaxin are significantly increased in AMD patients.AMD is an incurable eye disease that is the leading cause of blindness for those aged 55 and older in the United States, affecting more than 10 million Americans. The early detection of AMD biomarkers in serum would identify individuals who are at high risk for development of AMD to challenge the course of the disease through life-style changes or therapeutics.


Innovation Details
 

File Number: SERI-234 

Other Information:

Investigator(s)
M.D. Kameran Lashkari

Contact
Mary Chatterton, Director of Corporate Alliances. mary.chatterton@schepens.harvard.edu.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

12,883 members 17,322 innovations 176 organizations

Browse

William Garner, M.D., MPH - CEO of Urigen, N.A., Inc.

"The iBridge Network provides an important additional pathway for entrepreneurs to access university innovations that may otherwise have been lost. The transparency of this pathway between entrepreneurs..."  read more...